Tag Archives: roche

Rona Partners with Roche for ALK7-Targeting Asset; MetaVia Appoints New CMO; SAB-142 FDA Fast Track Designation

Three cardiometabolic-related news items have been observed: Rona Therapeutics entered into a partnership with Roche for an ALK7 asset to treat metabolic diseases (view press release); MetaVia appointed Sarah Browne as its new Chief Medical Officer (view press release); and SAB Bio received FDA Fast Track designation for the development of SAB-142 in Stage 3 T1DM (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

EASD 2026 Winners/Not Winners Analysis: Who Came Out on Top… and Who Didn’t?

Following EASD 2026 (Sep 28-Oct 2; Milan, Italy), FENIX has conducted a winners/not winners analysis, assessing which companies gained further momentum from the conference, remained static, or trended in the wrong direction. Spoiler alert: Lilly clearly came out on top, with EloraTZP setting a new efficacy benchmark for what may be achievable with an amylin + incretin combination. However, winning is not a zero-sum game…

This content is for Read Less members only.

Already a member? Log in here

EASD 2026 Key Press Releases (September 28)

On the first day of EASD 2026, six key news items were observed from Roche, Tandem Diabetes Care, Dexcom, Lilly, MindRank, and DreaMed Diabetes. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.

Already a member? Log in here

Onswik FDA Approval; Lilly Medicare GLP-1 Bridge Program Market Share; BI + WHO Global Metabolic Health Collaboration; Roche + Atavistik Partner for Allosteric Drug Discovery; Aqua Medical T2DM Endoscopic Procedure; Biolinq Shine OTC FDA Clearance; Rezera RESOLVE-1 AHA Presentation

A series of cardiometabolic-related news items has been observed from Lilly, BI/WHO, Roche/Atavistik Bio, Aqua Medical, Biolinq, and Rezera. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Viking Pops 31% on Maintenance Data; Roche Ph2 Enicepatide Results; New Lilly Manufacturing Facility; Obi Approved in the EU; Petrelintide Ph3 Program

A series of cardiometabolic-related news items has been observed from Viking Therapeutics, Roche, Lilly, NewAmsterdam Pharma, and Zealand Pharma. The news items seemingly come hot on the heels of Novo’s obesity-centric Capital Markets Day held Monday. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Partners for Oral Drug Discovery; Bayer’s Kerendia Receives T1DM FDA Label Expansion; AbbVie’s Allergan Skincare + AOM Data; Roche Opens Boston CVRM Innovation Center

A series of cardiometabolic-related news items has been observed from Novo/Orbis, Bayer, AbbVie/Allergan Aesthetics, and Roche. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Roche Licenses Muscle-Preservation AOM from Hanmi; Foundayo UK Launch; Lilly Initiates Second Ph3 Brenipatide MDD Study; Lexicon Receives Third LX9851 Milestone Payment; Biomea Completes COVALENT-211 Enrollment

A series of cardiometabolic-related news items has been observed from Roche/Hanmi, Lilly, Lexicon, and Biomea Fusion. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Initiates Ph3 OASIS 5 Study; AZ Initiates Ph3 Amylin Program; Roche Makes Another Manufacturing Investment; NICE Endorses Lilly’s QW Insulin; Hansoh Discovers New Obesity Assets

A series of cardiometabolic-related news items has been observed from Novo Nordisk, AstraZeneca, Roche/Genentech, Lilly, and Hansoh Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Roche Q2 ’26 Earnings; New Retatrutide Ph3 Data; Trinity Biotech Partners with Latch Medical; Dexcom Joins FDA TEMPO Pilot Program

A series of cardiometabolic-related news items has been observed from Roche, Lilly, Trinity Biotech, and Dexcom. Below, FENIX provides highlights and insights for the respective news items, including insight into Lilly’s retatrutide regulatory strategy.

This content is for Read Less members only.

Already a member? Log in here

June CHMP Meeting Highlights; New Enicepatide China-Based Ph3 Obesity Study; Cirius Initiates Ph2 Dosing in T1DM Study

Three cardiometabolic-related news items have been observed: The CHMP highlights for this month’s meeting (June 22-25) have been released (view highlights), Roche initiated a new Ph3 China-based enicepatide obesity study (view CT.gov record), and Cirius Therapeutics initiated enrollment and dosing in its Ph2 T1DM study (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here